CD24 and AL amyloidosis: Another specific CAR T-cell BCMA (B cell maturation antigen)-CD24 CAR-T, a novel multiple myeloma immunotherapy, was developed by Fumou Sun et al. They have demonstrated strong cytotoxic activity and selectivity for multiple myeloma cells in vitro and in vivo (293).